It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Bone metastasis is an incurable complication of breast cancer. In advanced stages, patients with estrogen-positive tumors experience a significantly higher incidence of bone metastasis (>87%) compared to estrogen-negative patients (<56%). To understand the mechanism of this bone-tropism of ER+ tumor, and to identify liquid biopsy biomarkers for patients with high risk of bone metastasis, the secreted extracellular vesicles and cytokines from bone-tropic breast cancer cells are examined in this study. Both exosomal miR-19a and Integrin-Binding Sialoprotein (IBSP) are found to be significantly upregulated and secreted from bone-tropic ER+ breast cancer cells, increasing their levels in the circulation of patients. IBSP is found to attract osteoclast cells and create an osteoclast-enriched environment in the bone, assisting the delivery of exosomal miR-19a to osteoclast to induce osteoclastogenesis. Our findings reveal a mechanism by which ER+ breast cancer cells create a microenvironment favorable for colonization in the bone. These two secreted factors can also serve as effective biomarkers for ER+ breast cancer to predict their risks of bone metastasis. Furthermore, our screening of a natural compound library identifies chlorogenic acid as a potent inhibitor for IBSP-receptor binding to suppress bone metastasis of ER+ tumor, suggesting its preventive use for bone recurrence in ER+ patients.
Bone metastasis is a major complication of breast cancer (BC) and ER+ tumors have a higher incidence of bone metastasis than ER− tumors. Here, the authors report that miR‐19a in exosomes and the bone matrix protein, IBSP, are upregulated and secreted by bone tropic ER+ BC cells, where they cooperatively induce osteoclastogenesis and promote bone colonization.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details






1 Wake Forest University School of Medicine, Department of Cancer Biology, Winston-Salem, USA (GRID:grid.241167.7) (ISNI:0000 0001 2185 3318)
2 Wake Forest University School of Medicine, Department of Cancer Biology, Winston-Salem, USA (GRID:grid.241167.7) (ISNI:0000 0001 2185 3318); Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Mammary Department, Shanghai, China (GRID:grid.412585.f) (ISNI:0000 0004 0604 8558)
3 Wake Forest University School of Medicine, Department of Cancer Biology, Winston-Salem, USA (GRID:grid.241167.7) (ISNI:0000 0001 2185 3318); Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, People’s Hospital of Henan University, Department of Breast Surgery, Zhengzhou, China (GRID:grid.414011.1) (ISNI:0000 0004 1808 090X)
4 Wake Forest University School of Medicine, Department of Cancer Biology, Winston-Salem, USA (GRID:grid.241167.7) (ISNI:0000 0001 2185 3318); The First Affiliated Hospital of Zhengzhou University, Department of Breast Surgery, Zhengzhou, China (GRID:grid.412633.1)
5 Jikei University School of Medicine, Department of Pathology, Minato City, Japan (GRID:grid.411898.d) (ISNI:0000 0001 0661 2073)
6 University of Mississippi Medical Center, Cancer Institute, Jackson, USA (GRID:grid.410721.1) (ISNI:0000 0004 1937 0407)